There are nonpharmacological approaches to managing behavioral and psychological symptoms of dementia and the difficulties associated with evaluating and implementing these approaches.
The AMA's Code of Medical Ethics' opinion on the use of databanks in genomic research requires informed consent by groups and individuals who are subjects of research.
Presymptomatic genetic testing for neurodegenerative diseases can help patients make effective treatment decisions, but the medical profession needs to ensure that the increasing use of the tests is done responsibly.